Abstract
Hepatocellular carcinoma (HCC) is one of the most common and deadly malignancies worldwide. HCC is a highly vascularized malignant tumor providing a rationale to consider angiogenesis as a therapeutic target. Anti-angiogenic strategies include locoregional and systemic treatments in HCC. Depending on the stage of the disease, different anti-angiogenic approaches are currently being employed in the treatment of HCC.
For patients at intermediate stage disease, transarterial chemoembolization (TACE) has been widely accepted as the standard of care and is the most common therapy for this patient group. TACE is a locoregional intervention, and its main mechanism of action is the embolization of the tumor-feeding arteries. For patients with advanced HCC, the multiprotein kinase inhibitors sorafenib and regorafenib provide systemic treatment options. Their efficacy in terms of survival prolongation has been shown in the palliative setting. Both drugs target among others the receptor of the vascular endothelial growth factor (VEGF), and their antitumor efficacy is believed to partly depend on the anti-angiogenic properties.
Similar content being viewed by others
References
Abou-Alfa GK, Cheng AL, Meyer T, El-Khoueiry AB, Ikeda M, Chun HG, Furuse J et al (2015) Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). J Clin Oncol 33
Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O et al (2015) Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol 62:855–862
Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr et al (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369–378
Bosetti C, Turati F, La Vecchia C (2014) Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 28:753–770
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821–829
Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022
Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V et al (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49:3412–3419
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M et al (2015) Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172–179
Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I et al (2016) Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int 36(5):729–736
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31:4067–4075
El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127
Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800
Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800
Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC (2012) Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 7
Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264
Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H et al (2014) How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 61:1287–1296
Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H et al (2014) How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 61:1287–1296
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517–3524
Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A et al (2013) A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24:2565–2570
Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A et al (2013) A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24:2565–2570
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595
Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao LC, Abdalla EK et al (2011) Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29:3892–3899
Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y et al (2009) Role of overexpression of CD151 and/or c-met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491–503
Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtlander T et al (2016) Experience from a real-life cohort: outcome of patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol:1–22
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106–116
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090–1098
Lencioni R, Marrero J, Venook A, Ye SL, Kudo M (2010) Design and rationale for the non-interventional global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with Sorafenib (GIDEON) study. Int J Clin Pract 64:1034–1041
Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516
Llovet JM, Pena CEA, Lathia CD, Shan M, Meinhardt G, Bruix J, Grp SIS (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2290–2300
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
Malek NP, Schmidt S, Huber P, Manns MP, Greten TF (2014) The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 111:101–106
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N et al (2013) A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 108:1252–1259
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35:2155–2166
Park Y, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Park YE et al (2016) Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 36:100–107
Ravi S, Singal AK (2014) Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid 9:81–87
Raymond E, Faivre S, Douillard J, Boucher E, Lim H, Kim J, Lanzalone S et al (2007) Phase II trial of the efficacy and safety of sunitinib malate monotherapy in unresectable hepatocellular carcinoma. Ann Oncol 18:Vii15–Vii15
Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63
Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI et al (2008) Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99:2037–2044
Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H et al (2013) The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57:2261–2273
Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, Lee Y et al (2012) Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30
Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J et al (2016) Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int 10:501–510
Zeng J, Lv L, Mei ZC (2016) Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 40(6):688–697
Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, et al. (2016) Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score. JAMA Oncol
Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP et al (2013) A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19:6614–6623
Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E et al (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH trial. Clin Cancer Res 22:4870–4879
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Kirstein, M.M., Vogel, A. (2017). Anti-angiogenics in Hepatocellular Cancer Therapy. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-31215-6_23-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-31215-6_23-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31215-6
Online ISBN: 978-3-319-31215-6
eBook Packages: Springer Reference MedicineReference Module Medicine